| Literature DB >> 30756069 |
Wissam Al-Janabi1, Renee Krebs1, Ximena Arcila-Londono1, Iram Zaman1, Bashiruddin K Ahmad1.
Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is a highly malignant glial tumour classified by the World Health Organization (WHO) as a stage IV astrocytoma. It varies in shape and size and can be cystic, vascular and necrotic. It often appears as a ring-enhancing lesion on magnetic resonance imaging (MRI). The most common symptoms of GBM, such as headache, vomiting and seizures, are due to increased intracranial pressure. The objective of this case report is to describe an atypical presentation of GBM. CASE REPORT: A 53-year-old woman of Italian origin presented with a 2-week history of lack of coordination in her hands and some difficulty in speech. Electromyography for assessment of her arms and cranial bulbar function was normal. However, 2 days later, the patient presented to the emergency department with progressive weakness in her left arm and leg as well as difficulty in speech. Mild left facial asymmetry was noted. A brain MRI revealed a right frontal mass. Stereotactic surgical resection was performed 2 days later, and biopsy confirmed the diagnosis of GBM. Although headache and other features of raised intracranial pressure are the most common initial symptoms of GBM, any atypical neurological or psychiatric presentation in an adult patient should raise suspicion for this tumour.Entities:
Keywords: Glioblastoma multiforme; World Health Organization; cerebrospinal fluid; emergency department; primary care physician
Year: 2018 PMID: 30756069 PMCID: PMC6346815 DOI: 10.12890/2018_000954
Source DB: PubMed Journal: Eur J Case Rep Intern Med ISSN: 2284-2594
Figure 1Magnetic resonance imaging clearly shows the right frontal lobe mass extending to the corpus callosum
Figure 2Histopathology: (1) H&E stain reveals the tumour with necrosis; (2) GFAP immunostaining is positive for tumour cells; a blood vessel with negative staining shows microvascular proliferation; (3) MIB-1 immunostaining of numerous tumour cells. Molecular information: MIB proliferation index 20%. IDH1 R123H (IHC): negative. IDH1 (NGS): negative; EGFRvIII mutation: negative; MGMT promoter methylation: negative